查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1717883

按治療類型、適應症類型和最終用戶分類的 Alpha-甘露醣儲積症市場 - 2025-2030 年全球預測

Alpha Mannosidosis Market by Therapy Type, Indication Type, End-User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 194 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023 年，α-甘露醣儲積症市場規模為 3.3066 億美元，預計 2024 年將成長至 3.7635 億美元，複合年成長率為 16.06%，預計到 2030 年將達到 9.3846 億美元。

主要市場統計數據
基準年2023年 3.3066億美元
預計年份：2024年 3.7635億美元
預測年份 2030 9.3846億美元
複合年成長率（%） 16.06%

α-甘露醣儲積症是罕見代謝疾病研究中最具挑戰性且最令人著迷的領域之一。近年來，隨著診斷和治療方法的進步，人們對闡明該疾病的發病機制的興趣日益濃厚。目前的研究旨在闡明這種複雜疾病的分子基礎並確定潛在的治療方法。隨著全球醫學界為變革性突破做好準備，現在有大量數據可用於幫助制定研究和商業投資策略。

在這種不斷變化的情況下，了解疾病機制和描述治療前景的需求變得至關重要。新技術、嚴格的臨床測試以及基因檢測的進步正在幫助臨床醫生做出更快、更準確的診斷。同時，監管變化、主要相關人員參與度的提高以及以患者為中心的護理的有力推動繼續推動市場發展。這篇全面的評論探討了 Alpha 甘露醣儲積症市場的發展、障礙和機會，為對當前情勢和未來前景的明智分析奠定了基礎。

改變α-甘露醣儲積症市場

近年來，α-甘露醣儲積症的治療和管理方法發生了重大變化。在過去十年中，精準醫療發生了重大轉變，這不僅改變了治療方式，也改變了更廣泛的醫療保健提供模式。技術創新正在激發人們對先進治療方法和新治療模式的興趣。例如，基因治療方法的進步和改進的酵素替代通訊協定極大地改變了傳統的治療藍圖。

這種轉變很大程度上是由於對疾病基因體學的理解不斷加深，加速了標靶治療納入主流治療方法。監管環境也在改善，監管機構採用更靈活的核准途徑，讓人們可以更快獲得可能改變生活的治療方法。日益激烈的競爭和不斷湧入的新臨床數據正在推動市場動態演變，要求相關人員靈活地收集資訊。如今開展研究和治療方法的方式截然不同，標誌著從傳統的一刀切方法轉向量身定做的精準解決方案的轉變。

此外，生物技術的進步和臨床合作的增加正在加快創新的步伐。現代臨床檢測方法和增強的診斷工具正在被整合到一個更具協作性的生態系統中，將學術界、工業界和醫療保健提供者聚集在一起。這種綜合努力不僅縮短了從研究到市場的時間，而且為更細緻的個人化患者照護鋪平了道路。

α-甘露醣儲積症市場的關鍵細分洞察

關鍵細分洞察是策略性理解 Alpha 甘露醣儲積症市場的重要指南。該分析深入探討了推動市場動態的多個細分維度。其中一項細分是根據治療類型對市場進行評估，檢查骨髓移植和酵素替代療法等細分領域。這些治療方法代表了隨著研究突破和臨床需求而快速發展的尖端解決方案。

市場根據適應症類型進一步細分，深入了解疾病的各種臨床表現。這包括區分 I、II 和 III 型 α-甘露甘露醣儲積症貯積症，每種類型都有獨特的臨床挑戰，需要個人化的治療策略。這種細緻的分析可以全面了解患者的反應、病情進展和治療結果的變化。

此外，透過對醫院和專科診所市場的最終用戶細分，可以了解治療方式的重要見解。這種分層方法有助於了解基礎設施、臨床專業知識和資源分配的變化。透過整合治療、適應症和最終用戶維度的考慮因素，細分分析提供了一個重要的視角，可以透過它來考慮投資重點、識別市場差距和評估競爭格局。這些詳細的細分策略的融合凸顯了在複雜的護理環境中個人化方法的重要性。

目錄

第1章 引言

第2章調查方法

第3章執行摘要

第4章 市場概述

第5章 市場洞察

  • 市場動態
    • 驅動程式
      • 人們對罕見疾病的認知和了解不斷提高，促使人們對診斷和治療的興趣日益濃厚
      • 新興國家醫療基礎設施建設改善了診斷工具和治療設施的可近性
    • 限制因素
      • 治療α-甘露醣儲積症的費用高昂
    • 機會
      • 隨著臨床試驗的增加和主管機關流程的簡化，潛力將會增加
    • 任務
      • 新型 α-甘露甘露醣儲積症治療方法的監管核准流程複雜且漫長
  • 市場區隔分析
    • 治療類型：骨髓移植在α-甘露醣儲積症症治療的意義
    • 適應症類型：I型α-甘露甘露醣儲積症，最輕微的疾病
    • 最終使用者：醫院在α-甘露醣儲積症症診斷與管理中的作用
  • 波特五力分析
  • PESTEL分析
    • 政治
    • 經濟
    • 社會
    • 科技
    • 法律
    • 環境

6. α-甘露醣儲積症症市場（依治療類型）

  • 介紹
  • 骨髓移植
  • 酵素替代療法

第7章。 α-甘露甘露醣儲積症症市場（依適應症類型）

  • 介紹
  • I型α-甘露甘露醣儲積症
  • Ⅱ型α-甘露甘露醣儲積症
  • 第三型α-甘露甘露醣儲積症

8. α-甘露醣儲積症市場（依最終用戶分類）

  • 介紹
  • 醫院
  • 專科診所

9.美洲α-甘露甘露醣儲積症市場

  • 介紹
  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

10. 亞太地區α-甘露醣儲積症酶市場

  • 介紹
  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

11. 歐洲、中東和非洲 Alpha -甘露醣儲積症市場

  • 介紹
  • 丹麥
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 挪威
  • 波蘭
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第12章競爭格局

  • 2023年市場佔有率分析
  • 2023年FPNV定位矩陣
  • 競爭情境分析
  • 戰略分析與建議

公司名單

  • Abeona Therapeutics Inc.
  • Alexion Pharmaceuticals, Inc. by AstraZeneca PLC
  • Amicus Therapeutics, Inc.
  • BioMarin Pharmaceutical Inc.
  • CHIESI Farmaceutici SpA
  • Eli Lilly and Company
  • JCR Pharmaceuticals Co., Ltd.
  • Kamada Ltd.
  • Orchard Therapeutics PLC
  • Pfizer, Inc.
  • Protalix BIoTherapeutics
  • Quest Diagnostics Incorporated
  • Sanofi SA
  • Sarepta Therapeutics, Inc.
  • Takeda Pharmaceutical Company Limited
  • Ultragenyx Pharmaceutical Inc.
Product Code: MRR-C002B1C99848

The Alpha Mannosidosis Market was valued at USD 330.66 million in 2023 and is projected to grow to USD 376.35 million in 2024, with a CAGR of 16.06%, reaching USD 938.46 million by 2030.

KEY MARKET STATISTICS
Base Year [2023] USD 330.66 million
Estimated Year [2024] USD 376.35 million
Forecast Year [2030] USD 938.46 million
CAGR (%) 16.06%

Alpha Mannosidosis remains one of the most challenging and yet compelling areas in rare metabolic disease research. In recent years, there has been an increasing focus on understanding the disease's pathology along with advances in diagnostic and treatment modalities. Current research is aimed at unraveling the molecular basis of this complex disorder and identifying potential therapeutic approaches. As the global healthcare community gears up for innovative breakthroughs, an abundance of data is now available to help shape strategies for research and commercial investments.

In this evolving scenario, the need to understand disease mechanisms and map the treatment landscape has become paramount. Emerging technologies, rigorous clinical trials, and advancements in genetic testing have converged to help clinicians make earlier and more accurate diagnoses. At the same time, regulatory shifts, increased involvement of key stakeholders, and a stronger push towards patient-centric care continue to drive the market. This comprehensive review explores the developments, hurdles, and opportunities across the Alpha Mannosidosis market, setting the stage for an informed analysis of both current conditions and future prospects.

Transformative Shifts in the Therapeutic Landscape

Recent transformative shifts have redefined the approach to treating and managing Alpha Mannosidosis. Over the past decade, there has been a significant pivot towards precision medicine, which has stirred transformation not just in treatment methods but also in the broader healthcare delivery framework. Innovations have spurred greater interest in advanced therapies and novel treatment paradigms. For instance, the progression in gene therapy methods and the refinement of enzyme replacement protocols have altered the conventional treatment roadmap significantly.

These shifts are largely fueled by an increased understanding of disease genomics, which is propelling the integration of targeted therapies into mainstream treatment regimens. The landscape has also seen regulatory bodies adopting more flexible approval pathways, allowing faster access to potentially life-changing therapies. With heightened competition and the continuous influx of new clinical data, the market is in a state of dynamic evolution, necessitating that stakeholders remain agile and informed. The way research is conducted and therapies are delivered today is markedly different from the past, signifying a transition from traditional, one-size-fits-all approaches to tailored, precision-focused solutions.

Furthermore, advancements in biotechnology and an increasing number of clinical collaborations have ramped up the pace of innovation. Modern clinical trial methodologies and enhanced diagnostic tools now feed into a more collaborative ecosystem where academia, industry, and healthcare providers work in tandem. These integrative efforts are not only reducing the time from research to market but are also opening nuanced avenues for personalized patient care.

Key Segmentation Insights in the Alpha Mannosidosis Market

In developing a strategic understanding of the Alpha Mannosidosis market, critical segmentation insights provide indispensable guidance. The analysis delves into multiple segmentation dimensions that drive market dynamics. One segmentation evaluates the market based on therapy type, exploring areas such as bone marrow transplantation and enzyme replacement therapy. These treatment approaches represent front-line solutions that are evolving rapidly in response to research breakthroughs and clinical needs.

The market is further segmented based on indication type, providing a thorough investigation into the various clinical manifestations of the disease. This includes differentiating between Type I, Type II, and Type III Alpha Mannosidosis, each presenting unique clinical challenges and requiring tailored treatment strategies. Such granularity in analysis ensures that variations in patient response, disease progression, and treatment efficacy are comprehensively understood.

Additionally, segmentation by the end-user, which studies the market across hospitals and specialty clinics, offers essential insights into how treatment is delivered. This layered approach helps in understanding variations in infrastructure, clinical expertise, and resource allocation. By weaving together insights across therapy, indication, and end-user dimensions, the segmentation analysis provides a critical lens through which to view investment priorities, identify market gaps, and assess the competitive environment. The convergence of these detailed segmentation strategies underscores the importance of personalized approaches in a complex therapeutic landscape.

Based on Therapy Type, market is studied across Bone Marrow Transplantation and Enzyme Replacement Therapy.

Based on Indication Type, market is studied across Type I Alpha Mannosidosis, Type II Alpha Mannosidosis, and Type III Alpha Mannosidosis.

Based on End-User, market is studied across Hospitals and Specialty Clinics.

Regional Insights across Global Markets

An essential component of understanding the Alpha Mannosidosis market involves an in-depth look at regional trends, where differing healthcare systems and demographic characteristics contribute to unique market dynamics. Insights drawn from major regions such as the Americas, Europe, Middle East & Africa, and Asia-Pacific reveal significant variations in disease prevalence, treatment infrastructure, and regulatory environments.

In the Americas, the market is buoyed by advanced healthcare infrastructure and a strong emphasis on innovation in treatment. Rapid integration of clinical trial outcomes into active treatment protocols is indicative of the region's commitment to advancing patient care. Europe, Middle East & Africa, and Asia-Pacific are also witnessing dynamic shifts, supported by collaborative networks between research institutions and industry. Each of these regions exhibits a robust appetite for next-generation therapies and has tailored policies that encourage faster adoption of advanced treatment modalities.

This global perspective not only highlights where clinical practice is pioneering but also emphasizes the need for customized regional strategies for market penetration, investment, and regulatory navigation. These insights serve as crucial indicators for stakeholders planning cross-border ventures and attempting to reconcile the diverse economic and cultural landscapes influencing disease management.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Finland, France, Germany, Israel, Italy, Netherlands, Norway, Poland, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

Insights on Leading Companies in the Alpha Mannosidosis Treatment Arena

The competitive landscape in the Alpha Mannosidosis market features an array of industry-leading companies that are continuously redefining therapeutic benchmarks. Notable players include Abeona Therapeutics Inc., which has carved a niche in pioneering gene-based and regenerative therapies. Alexion Pharmaceuticals, Inc. by AstraZeneca PLC remains entrenched in the development of rare disease treatments while Amicus Therapeutics, Inc. and BioMarin Pharmaceutical Inc. continue to push forward breakthrough research in enzyme replacement therapies.

Other significant contributors in this space such as CHIESI Farmaceutici S.p.A. and Eli Lilly and Company are investing heavily in clinical trials and innovating patient care models. In addition, JCR Pharmaceuticals Co., Ltd. and Kamada Ltd. offer innovative perspectives on the application of bone marrow transplantation in critical cases. Orchard Therapeutics PLC and Pfizer, Inc. bring robust research capabilities and significant market reach while Protalix Biotherapeutics and Quest Diagnostics Incorporated emphasize the importance of diagnostic precision in early intervention strategies. Companies like Sanofi S.A., Sarepta Therapeutics, Inc., Takeda Pharmaceutical Company Limited, and Ultragenyx Pharmaceutical Inc. are contributing to an integrated ecosystem that balances scientific rigor with patient-centric therapy development.

Together, these companies help shape a competitive market environment that is defined by collaborative innovation, clinical excellence, and strategic partnerships. Their diverse portfolios and commitment to advancing treatment options are pivotal in pushing the boundaries of what is possible for Alpha Mannosidosis.

The report delves into recent significant developments in the Alpha Mannosidosis Market, highlighting leading vendors and their innovative profiles. These include Abeona Therapeutics Inc., Alexion Pharmaceuticals, Inc. by AstraZeneca PLC, Amicus Therapeutics, Inc., BioMarin Pharmaceutical Inc., CHIESI Farmaceutici S.p.A., Eli Lilly and Company, JCR Pharmaceuticals Co., Ltd., Kamada Ltd., Orchard Therapeutics PLC, Pfizer, Inc., Protalix Biotherapeutics, Quest Diagnostics Incorporated, Sanofi S.A., Sarepta Therapeutics, Inc., Takeda Pharmaceutical Company Limited, and Ultragenyx Pharmaceutical Inc.. Actionable Recommendations for Industry Leaders

For industry leaders looking to capitalize on the evolving Alpha Mannosidosis market, several actionable recommendations stand out. Firstly, investing in collaborative research initiatives is paramount. Establishing partnerships across academic institutions, biotechnology firms, and clinical centers can expedite the journey from discovery to treatment, ensuring that innovative therapies reach patients swiftly and safely.

Next, it is essential to adopt a segmented approach in strategy development. By tailoring offerings according to therapy type, indication, and end-user dynamics, companies can better address specific market needs. Incorporating flexible frameworks that allow for rapid adaptability to regulatory changes and evolving clinical data will be a significant competitive advantage. Leaders should also emphasize precision in recognizing regional market variations. In-depth market analysis, based on divergent healthcare infrastructures across the Americas, Europe, Middle East & Africa, and Asia-Pacific regions, will enable more targeted, effective strategies for market entry and expansion.

Furthermore, investing in cutting-edge technology for research and development, such as next-generation sequencing and advanced proteomics, can boost the capabilities required for early diagnosis and personalized treatment planning. Lastly, maintaining a robust dialogue with regulatory agencies and participating in policy advisory panels will not only shape favorable regulatory environments but also enhance the credibility and market positioning of companies. These combined efforts can create a virtuous cycle of innovation, investment, and patient benefit, thereby ensuring sustained market success.

Conclusion: A Strategic View of Future Opportunities

In summing up, the Alpha Mannosidosis market stands at the cusp of a transformative era driven by groundbreaking research, innovative treatment approaches, and dynamic market restructuring. The current wave of innovation-from enhanced diagnostic capabilities to the development of targeted therapies-provides not only new hope for patients but also fertile ground for investment and strategic growth.

A convergent approach, uniting scientific discovery with robust market strategies, is redefining how care is delivered to patients with this rare condition. Stakeholders now have a clearer framework to understand the interplay between therapy types, clinical indications, and the evolving role of end-users. Regional nuances further underline the need for adaptable strategies that align with local healthcare policies and market infrastructures.

Looking ahead, the future of the Alpha Mannosidosis market is promising. The blend of medical innovation and strategic market planning positions the industry well to overcome existing challenges while exploring new therapeutic frontiers. Through continued investment, collaboration, and a relentless focus on patient-centric care, the market is set to experience a new era of progress and prosperity.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising awareness and understanding of rare diseases contributing to increased diagnosis and interest in treatments
      • 5.1.1.2. Growing healthcare infrastructures in developing countries improve access to diagnostic tools and treatment facilities
    • 5.1.2. Restraints
      • 5.1.2.1. High cost associated with the treatment of alpha mannosidosis
    • 5.1.3. Opportunities
      • 5.1.3.1. Increasing potential with rising clinical trials and process simplification by competent authority
    • 5.1.4. Challenges
      • 5.1.4.1. Complex and lengthy regulatory approval processes for new alpha mannosidosis treatments
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Therapy Type: Significance of bone marrow transplantation in the treatment of alpha mannosidosis
    • 5.2.2. Indication Type: Type I alpha mannosidosis as a mildest form of disorder
    • 5.2.3. End-User: Role of hospitals in the diagnosis and management of alpha mannosidosis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Alpha Mannosidosis Market, by Therapy Type

  • 6.1. Introduction
  • 6.2. Bone Marrow Transplantation
  • 6.3. Enzyme Replacement Therapy

7. Alpha Mannosidosis Market, by Indication Type

  • 7.1. Introduction
  • 7.2. Type I Alpha Mannosidosis
  • 7.3. Type II Alpha Mannosidosis
  • 7.4. Type III Alpha Mannosidosis

8. Alpha Mannosidosis Market, by End-User

  • 8.1. Introduction
  • 8.2. Hospitals
  • 8.3. Specialty Clinics

9. Americas Alpha Mannosidosis Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Alpha Mannosidosis Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Alpha Mannosidosis Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Finland
  • 11.4. France
  • 11.5. Germany
  • 11.6. Israel
  • 11.7. Italy
  • 11.8. Netherlands
  • 11.9. Norway
  • 11.10. Poland
  • 11.11. Russia
  • 11.12. Saudi Arabia
  • 11.13. South Africa
  • 11.14. Spain
  • 11.15. Sweden
  • 11.16. Switzerland
  • 11.17. Turkey
  • 11.18. United Arab Emirates
  • 11.19. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
    • 12.3.1. Dyne Therapeutics showcases the innovative FORCE platform in enzyme delivery solutions
    • 12.3.2. Newborn screening for lysosomal storage disorders expanded in Korea
    • 12.3.3. JCR Pharmaceuticals showcases JR-141 (Pabinafusp Alfa) and other investigational treatments for lysosomal storage disorders
    • 12.3.4. Chiesi Global Rare Diseases presented long-term data on Velmanase Alfa
    • 12.3.5. Innovative partnership breakthrough in crossing the blood-brain barrier for treating lysosomal storage disorders
    • 12.3.6. Kwangdong advances rare disease treatments in Korea through strategic partnership with Chiesi Farmaceutici
    • 12.3.7. FDA approval of Lamzede unveils promising therapy for rare genetic disorder alpha-mannosidosis
  • 12.4. Strategy Analysis & Recommendation
    • 12.4.1. Chiesi Farmaceutici S.p.A.
    • 12.4.2. BioMarin Pharmaceutical Inc.
    • 12.4.3. Sanofi S.A.

Companies Mentioned

  • 1. Abeona Therapeutics Inc.
  • 2. Alexion Pharmaceuticals, Inc. by AstraZeneca PLC
  • 3. Amicus Therapeutics, Inc.
  • 4. BioMarin Pharmaceutical Inc.
  • 5. CHIESI Farmaceutici S.p.A.
  • 6. Eli Lilly and Company
  • 7. JCR Pharmaceuticals Co., Ltd.
  • 8. Kamada Ltd.
  • 9. Orchard Therapeutics PLC
  • 10. Pfizer, Inc.
  • 11. Protalix Biotherapeutics
  • 12. Quest Diagnostics Incorporated
  • 13. Sanofi S.A.
  • 14. Sarepta Therapeutics, Inc.
  • 15. Takeda Pharmaceutical Company Limited
  • 16. Ultragenyx Pharmaceutical Inc.

LIST OF FIGURES

  • FIGURE 1. ALPHA MANNOSIDOSIS MARKET MULTI-CURRENCY
  • FIGURE 2. ALPHA MANNOSIDOSIS MARKET MULTI-LANGUAGE
  • FIGURE 3. ALPHA MANNOSIDOSIS MARKET RESEARCH PROCESS
  • FIGURE 4. ALPHA MANNOSIDOSIS MARKET SIZE, 2023 VS 2030
  • FIGURE 5. GLOBAL ALPHA MANNOSIDOSIS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 6. GLOBAL ALPHA MANNOSIDOSIS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 7. GLOBAL ALPHA MANNOSIDOSIS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL ALPHA MANNOSIDOSIS MARKET SIZE, BY THERAPY TYPE, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL ALPHA MANNOSIDOSIS MARKET SIZE, BY THERAPY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL ALPHA MANNOSIDOSIS MARKET SIZE, BY INDICATION TYPE, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL ALPHA MANNOSIDOSIS MARKET SIZE, BY INDICATION TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL ALPHA MANNOSIDOSIS MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL ALPHA MANNOSIDOSIS MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. AMERICAS ALPHA MANNOSIDOSIS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. AMERICAS ALPHA MANNOSIDOSIS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. UNITED STATES ALPHA MANNOSIDOSIS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 17. UNITED STATES ALPHA MANNOSIDOSIS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC ALPHA MANNOSIDOSIS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. ASIA-PACIFIC ALPHA MANNOSIDOSIS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA ALPHA MANNOSIDOSIS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA ALPHA MANNOSIDOSIS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. ALPHA MANNOSIDOSIS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 23. ALPHA MANNOSIDOSIS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. ALPHA MANNOSIDOSIS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL ALPHA MANNOSIDOSIS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL ALPHA MANNOSIDOSIS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL ALPHA MANNOSIDOSIS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. ALPHA MANNOSIDOSIS MARKET DYNAMICS
  • TABLE 7. GLOBAL ALPHA MANNOSIDOSIS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL ALPHA MANNOSIDOSIS MARKET SIZE, BY BONE MARROW TRANSPLANTATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL ALPHA MANNOSIDOSIS MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL ALPHA MANNOSIDOSIS MARKET SIZE, BY INDICATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL ALPHA MANNOSIDOSIS MARKET SIZE, BY TYPE I ALPHA MANNOSIDOSIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL ALPHA MANNOSIDOSIS MARKET SIZE, BY TYPE II ALPHA MANNOSIDOSIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL ALPHA MANNOSIDOSIS MARKET SIZE, BY TYPE III ALPHA MANNOSIDOSIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL ALPHA MANNOSIDOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL ALPHA MANNOSIDOSIS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL ALPHA MANNOSIDOSIS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. AMERICAS ALPHA MANNOSIDOSIS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 18. AMERICAS ALPHA MANNOSIDOSIS MARKET SIZE, BY INDICATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 19. AMERICAS ALPHA MANNOSIDOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 20. AMERICAS ALPHA MANNOSIDOSIS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 21. ARGENTINA ALPHA MANNOSIDOSIS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 22. ARGENTINA ALPHA MANNOSIDOSIS MARKET SIZE, BY INDICATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 23. ARGENTINA ALPHA MANNOSIDOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 24. BRAZIL ALPHA MANNOSIDOSIS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 25. BRAZIL ALPHA MANNOSIDOSIS MARKET SIZE, BY INDICATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 26. BRAZIL ALPHA MANNOSIDOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 27. CANADA ALPHA MANNOSIDOSIS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 28. CANADA ALPHA MANNOSIDOSIS MARKET SIZE, BY INDICATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 29. CANADA ALPHA MANNOSIDOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 30. MEXICO ALPHA MANNOSIDOSIS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 31. MEXICO ALPHA MANNOSIDOSIS MARKET SIZE, BY INDICATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 32. MEXICO ALPHA MANNOSIDOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 33. UNITED STATES ALPHA MANNOSIDOSIS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 34. UNITED STATES ALPHA MANNOSIDOSIS MARKET SIZE, BY INDICATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 35. UNITED STATES ALPHA MANNOSIDOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 36. UNITED STATES ALPHA MANNOSIDOSIS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 37. ASIA-PACIFIC ALPHA MANNOSIDOSIS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 38. ASIA-PACIFIC ALPHA MANNOSIDOSIS MARKET SIZE, BY INDICATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 39. ASIA-PACIFIC ALPHA MANNOSIDOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 40. ASIA-PACIFIC ALPHA MANNOSIDOSIS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 41. AUSTRALIA ALPHA MANNOSIDOSIS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 42. AUSTRALIA ALPHA MANNOSIDOSIS MARKET SIZE, BY INDICATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 43. AUSTRALIA ALPHA MANNOSIDOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 44. CHINA ALPHA MANNOSIDOSIS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 45. CHINA ALPHA MANNOSIDOSIS MARKET SIZE, BY INDICATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 46. CHINA ALPHA MANNOSIDOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 47. INDIA ALPHA MANNOSIDOSIS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 48. INDIA ALPHA MANNOSIDOSIS MARKET SIZE, BY INDICATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 49. INDIA ALPHA MANNOSIDOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 50. INDONESIA ALPHA MANNOSIDOSIS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 51. INDONESIA ALPHA MANNOSIDOSIS MARKET SIZE, BY INDICATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 52. INDONESIA ALPHA MANNOSIDOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 53. JAPAN ALPHA MANNOSIDOSIS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 54. JAPAN ALPHA MANNOSIDOSIS MARKET SIZE, BY INDICATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 55. JAPAN ALPHA MANNOSIDOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 56. MALAYSIA ALPHA MANNOSIDOSIS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 57. MALAYSIA ALPHA MANNOSIDOSIS MARKET SIZE, BY INDICATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 58. MALAYSIA ALPHA MANNOSIDOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 59. PHILIPPINES ALPHA MANNOSIDOSIS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 60. PHILIPPINES ALPHA MANNOSIDOSIS MARKET SIZE, BY INDICATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 61. PHILIPPINES ALPHA MANNOSIDOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 62. SINGAPORE ALPHA MANNOSIDOSIS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 63. SINGAPORE ALPHA MANNOSIDOSIS MARKET SIZE, BY INDICATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 64. SINGAPORE ALPHA MANNOSIDOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 65. SOUTH KOREA ALPHA MANNOSIDOSIS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 66. SOUTH KOREA ALPHA MANNOSIDOSIS MARKET SIZE, BY INDICATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 67. SOUTH KOREA ALPHA MANNOSIDOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 68. TAIWAN ALPHA MANNOSIDOSIS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 69. TAIWAN ALPHA MANNOSIDOSIS MARKET SIZE, BY INDICATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 70. TAIWAN ALPHA MANNOSIDOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 71. THAILAND ALPHA MANNOSIDOSIS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 72. THAILAND ALPHA MANNOSIDOSIS MARKET SIZE, BY INDICATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 73. THAILAND ALPHA MANNOSIDOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 74. VIETNAM ALPHA MANNOSIDOSIS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 75. VIETNAM ALPHA MANNOSIDOSIS MARKET SIZE, BY INDICATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 76. VIETNAM ALPHA MANNOSIDOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 77. EUROPE, MIDDLE EAST & AFRICA ALPHA MANNOSIDOSIS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 78. EUROPE, MIDDLE EAST & AFRICA ALPHA MANNOSIDOSIS MARKET SIZE, BY INDICATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 79. EUROPE, MIDDLE EAST & AFRICA ALPHA MANNOSIDOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 80. EUROPE, MIDDLE EAST & AFRICA ALPHA MANNOSIDOSIS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 81. DENMARK ALPHA MANNOSIDOSIS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 82. DENMARK ALPHA MANNOSIDOSIS MARKET SIZE, BY INDICATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 83. DENMARK ALPHA MANNOSIDOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 84. FINLAND ALPHA MANNOSIDOSIS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 85. FINLAND ALPHA MANNOSIDOSIS MARKET SIZE, BY INDICATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 86. FINLAND ALPHA MANNOSIDOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 87. FRANCE ALPHA MANNOSIDOSIS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 88. FRANCE ALPHA MANNOSIDOSIS MARKET SIZE, BY INDICATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 89. FRANCE ALPHA MANNOSIDOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 90. GERMANY ALPHA MANNOSIDOSIS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 91. GERMANY ALPHA MANNOSIDOSIS MARKET SIZE, BY INDICATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 92. GERMANY ALPHA MANNOSIDOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 93. ISRAEL ALPHA MANNOSIDOSIS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 94. ISRAEL ALPHA MANNOSIDOSIS MARKET SIZE, BY INDICATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 95. ISRAEL ALPHA MANNOSIDOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 96. ITALY ALPHA MANNOSIDOSIS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 97. ITALY ALPHA MANNOSIDOSIS MARKET SIZE, BY INDICATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 98. ITALY ALPHA MANNOSIDOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 99. NETHERLANDS ALPHA MANNOSIDOSIS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 100. NETHERLANDS ALPHA MANNOSIDOSIS MARKET SIZE, BY INDICATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 101. NETHERLANDS ALPHA MANNOSIDOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 102. NORWAY ALPHA MANNOSIDOSIS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 103. NORWAY ALPHA MANNOSIDOSIS MARKET SIZE, BY INDICATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 104. NORWAY ALPHA MANNOSIDOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 105. POLAND ALPHA MANNOSIDOSIS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 106. POLAND ALPHA MANNOSIDOSIS MARKET SIZE, BY INDICATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 107. POLAND ALPHA MANNOSIDOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 108. RUSSIA ALPHA MANNOSIDOSIS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 109. RUSSIA ALPHA MANNOSIDOSIS MARKET SIZE, BY INDICATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 110. RUSSIA ALPHA MANNOSIDOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 111. SAUDI ARABIA ALPHA MANNOSIDOSIS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 112. SAUDI ARABIA ALPHA MANNOSIDOSIS MARKET SIZE, BY INDICATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 113. SAUDI ARABIA ALPHA MANNOSIDOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 114. SOUTH AFRICA ALPHA MANNOSIDOSIS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 115. SOUTH AFRICA ALPHA MANNOSIDOSIS MARKET SIZE, BY INDICATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 116. SOUTH AFRICA ALPHA MANNOSIDOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 117. SPAIN ALPHA MANNOSIDOSIS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 118. SPAIN ALPHA MANNOSIDOSIS MARKET SIZE, BY INDICATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 119. SPAIN ALPHA MANNOSIDOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 120. SWEDEN ALPHA MANNOSIDOSIS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 121. SWEDEN ALPHA MANNOSIDOSIS MARKET SIZE, BY INDICATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 122. SWEDEN ALPHA MANNOSIDOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 123. SWITZERLAND ALPHA MANNOSIDOSIS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 124. SWITZERLAND ALPHA MANNOSIDOSIS MARKET SIZE, BY INDICATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 125. SWITZERLAND ALPHA MANNOSIDOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 126. TURKEY ALPHA MANNOSIDOSIS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 127. TURKEY ALPHA MANNOSIDOSIS MARKET SIZE, BY INDICATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 128. TURKEY ALPHA MANNOSIDOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 129. UNITED ARAB EMIRATES ALPHA MANNOSIDOSIS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 130. UNITED ARAB EMIRATES ALPHA MANNOSIDOSIS MARKET SIZE, BY INDICATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 131. UNITED ARAB EMIRATES ALPHA MANNOSIDOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 132. UNITED KINGDOM ALPHA MANNOSIDOSIS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 133. UNITED KINGDOM ALPHA MANNOSIDOSIS MARKET SIZE, BY INDICATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 134. UNITED KINGDOM ALPHA MANNOSIDOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 135. ALPHA MANNOSIDOSIS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 136. ALPHA MANNOSIDOSIS MARKET, FPNV POSITIONING MATRIX, 2023